Business Wire

GA-IDEMIA

10.2.2021 14:02:11 CET | Business Wire | Press release

Share
Honeywell and IDEMIA Announce Strategic Alliance to Develop Intelligent Building Offering

Honeywell (NYSE: HON) , a global leader in connected buildings, and IDEMIA, the global leader in Augmented Identity, today announced a strategic alliance to create and cultivate an intelligent building ecosystem that provides a more seamless and enhanced experience for operators and occupants alike. The alliance will integrate Honeywell’s security and building management systems with IDEMIA’s biometric-based access control systems to create frictionless, safer and more efficient buildings.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210210005454/en/

The Honeywell and IDEMIA alliance is intended to design solutions that will allow occupants to easily and securely have contactless engagement with a building – from vehicle recognition at the car park and automatic elevator calls to biometric-based access and personalized conference room settings. With a focus on security and data privacy, these next-generation solutions will provide occupants with a safer, more efficient and more enjoyable experience that will help building owners attract tenants.

“We recognize that our customers need to deliver business outcomes like managing complex security requirements and providing healthier, more productive environments,” said Manish Sharma, vice president, chief technology and chief product officer for Honeywell Building Technologies. “By working with IDEMIA we will create an intelligent building ecosystem that better addresses our customers’ key challenges and drives their desired outcomes. Whether it’s a commercial office building, a hospital or an airport, we have the ability to change the way people experience and interact with buildings for the better.”

“We look forward to expanding our long-standing relationship with Honeywell to bring greater value to our customers with more integrated solutions that make for a more seamless building experience,” said Matt Cole, CEO, Secure Enterprise Transactions Division, IDEMIA. “The ability for our technology to easily integrate with Honeywell safety and security systems will provide building owners and operators more insight and control into creating more efficient buildings, while putting the occupant experience first.”

IDEMIA’s field-proven AI-based products and solutions -- like MorphoWave TM , a contactless fingerprint device that scans four fingerprints in less than one second; VisionPass, the most advanced facial recognition terminal; or Augmented Vision, a biometric video analytics platform -- integrate with Honeywell security and building management systems. Honeywell’s systems include Pro-Watch Integrated Security Suite, MAXPRO Cloud and Enterprise Buildings Integrator.

Honeywell and IDEMIA will work together to deliver more powerful integrations through aligned product creation and joint product roadmaps. The integrated offerings will allow building operators to respond rapidly and effectively to alarms or incidents by providing an incident workflow package that allows Standard Operating Procedures (SOPs) to be configured, reducing compliance exceptions, security risks and response times.

IDEMIA products also support Honeywell’s Healthy Buildings solutions that help building owners improve building environments, operate more cleanly and safely and encourage sustained compliance with changing building standards, safety guidelines, government-issued regulations and a company's risk management policies. Honeywell's Healthy Buildings solutions provide a holistic view of a building's health based on key factors such as indoor air quality, occupant flow, personal protection equipment (PPE) analytics, contactless access, thermal screening, social distancing and sanitation efficacy.

To learn more about Honeywell and IDEMIA collaborations click here .

# # #

About IDEMIA

IDEMIA, the global leader in augmented identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.

Securing our identity has become mission critical in the world we live in today. By standing for augmented identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide augmented identity for international clients from financial, telecom, identity, public security and IoT sectors.

With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.

For more information, visit www.idemia.com or follow @IDEMIAGroup on Twitter.

About Honeywell Building Technologies

Honeywell Building Technologies (HBT) is a global business with more than 18,000 employees. HBT creates products, software and technologies found in more than 10 million buildings worldwide. Commercial building owners and operators use our technologies to help create safe, energy efficient, sustainable and productive facilities. For more news and information on Honeywell Building Technologies, visit http://www.honeywell.com/newsroom .

Honeywell (www.honeywell.com ) is a Fortune 100 technology company that delivers industry specific solutions that include aerospace products and services; control technologies for buildings and industry; and performance materials globally. Our technologies help aircraft, buildings, manufacturing plants, supply chains, and workers become more connected to make our world smarter, safer, and more sustainable. For more news and information on Honeywell, please visit www.honeywell.com/newsroom .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye